The estimated Net Worth of David V Goeddel is at least $1.7 Million dollars as of 15 November 2023. David Goeddel owns over 26,811 units of Ngm Biopharmaceuticals Inc stock worth over $1,462,787 and over the last 5 years he sold NGM stock worth over $0. In addition, he makes $240,368 as Lead independent director at Ngm Biopharmaceuticals Inc.
David has made over 39 trades of the Ngm Biopharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 26,811 units of NGM stock worth $18,231 on 15 November 2023.
The largest trade he's ever made was buying 984,161 units of Ngm Biopharmaceuticals Inc stock on 9 June 2022 worth over $13,286,174. On average, David trades about 136,130 units every 34 days since 2019. As of 15 November 2023 he still owns at least 949,862 units of Ngm Biopharmaceuticals Inc stock.
You can see the complete history of David Goeddel stock trades at the bottom of the page.
Dr. David V.N. Goeddel Ph.D. serves as Lead independent director of the Company. Dr. Goeddel became Lead Independent Director of our Board of Directors in September 2018, after having served as Chairman since January 2008, and served as our Chief Executive Officer from 2008 to 2010. Dr. Goeddel has been a Managing Partner of The Column Group (“TCG”), a venture capital partnership, since 2007. Dr. Goeddel co-founded Tularik in November 1991, was Vice President of Research until 1996 and Chief Executive Officer from 1996 through 2004. He served as Amgen’s first Senior Scientific Vice President until May 2006. Prior to Tularik, he was the first scientist hired by Genentech, and from 1978 to 1993 served in various positions, including Fellow, Staff Scientist and Director of Molecular Biology. Dr. Goeddel has served as a director at RAPT Therapeutics, Inc., a publicly-traded biotechnology company, since 2015. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences. Dr. Goeddel received a B.S. in Chemistry from the University of California, San Diego and a Ph.D. from the University of Colorado.
As the Lead independent director of Ngm Biopharmaceuticals Inc, the total compensation of David Goeddel at Ngm Biopharmaceuticals Inc is $240,368. There are 9 executives at Ngm Biopharmaceuticals Inc getting paid more, with David Woodhouse having the highest compensation of $2,092,150.
David Goeddel is 68, he's been the Lead independent director of Ngm Biopharmaceuticals Inc since 2018. There are no older and 17 younger executives at Ngm Biopharmaceuticals Inc.
David's mailing address filed with the SEC is 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO, CA, 94129.
Over the last 6 years, insiders at Ngm Biopharmaceuticals Inc have traded over $9,159,599 worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth $177,396,366 . The most active insiders traders include Peter Svennilson, David V Goeddel, and Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $171,092. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth $15,615.
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include: